View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Nov. 30, 2013	Jan. 02, 2014
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Nov. 30, 2013
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q2
Trading Symbol	ANGO
Entity Registrant Name	ANGIODYNAMICS INC
Entity Central Index Key	0001275187
Current Fiscal Year End Date	--05-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		35,310,966

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2013	Nov. 30, 2012	Nov. 30, 2013	Nov. 30, 2012
Income Statement [Abstract]
Net sales	$ 88,616	$ 87,007	$ 172,195	$ 170,423
Cost of sales	43,686	42,919	84,783	86,877
Gross profit	44,930	44,088	87,412	83,546
Operating expenses
Research and development	7,003	7,014	13,712	14,088
Sales and marketing	21,073	18,671	41,036	37,214
General and administrative	6,323	6,910	12,851	13,808
Amortization of intangibles	4,339	4,107	8,623	7,844
Change in fair value of contingent consideration	940	197	1,673	197
Acquisition, restructuring and other items, net	2,679	2,067	4,681	4,589
Medical device excise tax	999		1,975
Total operating expenses	43,356	38,966	84,551	77,740
Operating income	1,574	5,122	2,861	5,806
Other income (expenses)
Interest expense	(959)	(1,383)	(2,205)	(2,715)
Interest income		21		103
Other expense	(701)	(628)	(1,389)	(1,216)
Total other income (expenses)	(1,660)	(1,990)	(3,594)	(3,828)
(Loss) income before income tax (expense) benefit	(86)	3,132	(733)	1,978
Income tax expense (benefit)	13	1,163	(208)	730
Net (loss) income	$ (99)	$ 1,969	$ (525)	$ 1,248
(Loss) income per share
Basic	$ 0.00	$ 0.06	$ (0.01)	$ 0.04
Diluted	$ 0.00	$ 0.06	$ (0.01)	$ 0.04
Basic weighted average shares outstanding	35,132	34,827	35,041	34,765
Diluted weighted average shares outstanding	35,132	35,311	35,041	35,279

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2013	Nov. 30, 2012	Nov. 30, 2013	Nov. 30, 2012
Statement Of Income And Comprehensive Income [Abstract]
Net (loss) income	$ (99)	$ 1,969	$ (525)	$ 1,248
Other comprehensive income (loss), before tax:
Unrealized (loss) gain on interest rate swap	(522)	151	(203)	184
Unrealized gain (loss) on marketable securities		29		(1,059)
Foreign currency translation gain	70	82	140	123
Other comprehensive (loss) income, before tax	(452)	262	(63)	(752)
Income tax benefit (expense) related to items of other comprehensive income	193	(67)	75	324
Other comprehensive (loss) income, net of tax	(259)	195	12	(428)
Total comprehensive (loss) income, net of tax	$ (358)	$ 2,164	$ (513)	$ 820

Consolidated Balance Sheets - USD ($) $ in Thousands	Nov. 30, 2013	May 31, 2013
CURRENT ASSETS
Cash and cash equivalents	$ 15,173	$ 21,802
Marketable securities, at fair value	1,850	2,153
Total cash, cash equivalents, and marketable securities	17,023	23,955
Accounts receivable, net of allowances of $1,584 and $1,272 respectively	48,405	47,791
Inventories	60,052	55,062
Deferred income taxes	6,706	6,591
Prepaid expenses and other	9,387	8,117
Total current assets	141,573	141,516
PROPERTY, PLANT AND EQUIPMENT-AT COST, net	66,390	62,650
OTHER ASSETS	5,543	5,559
INTANGIBLE ASSETS, net	212,195	214,848
GOODWILL	359,736	355,458
DEFERRED INCOME TAXES, long term	9,507	11,007
PREPAID ROYALTIES	546	546
TOTAL ASSETS	795,490	791,584
CURRENT LIABILITIES
Accounts payable	28,336	24,522
Accrued liabilities	17,530	16,426
Current portion of long-term debt	5,000	7,500
Current portion of contingent consideration	12,221	9,207
Other current liabilities	5,992	5,782
Total current liabilities	69,079	63,437
LONG-TERM DEBT, revolving credit facility	41,410
LONG-TERM DEBT, term loan, net of current portion	93,750	135,000
DEFERRED INCOME TAXES, long term	1,166
Contingent consideration, net of current portion	60,171	65,842
Other long term liabilities	185	475
Total liabilities	265,761	264,754
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Preferred stock, par value $.01 per share, 5,000,000 shares authorized; no shares issued and outstanding
Common stock, par value $.01 per share, 45,000,000 shares authorized; issued and outstanding 35,305,229 and 35,060,351 shares at November 30, 2013 and May 31, 2013, respectively	353	351
Additional paid-in capital	503,964	500,554
Retained earnings	29,038	29,563
Treasury stock, 142,305 shares, at cost	(2,104)	(2,104)
Accumulated other comprehensive loss	(1,522)	(1,534)
Total stockholders' equity	529,729	526,830
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 795,490	$ 791,584

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Nov. 30, 2013	May 31, 2013
Statement Of Financial Position [Abstract]
Accounts receivable, allowances	$ 1,584	$ 1,272
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	45,000,000	45,000,000
Common stock, shares issued	35,305,229	35,060,351
Common stock, shares outstanding	35,305,229	35,060,351
Treasury stock, shares	142,305	142,305

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Nov. 30, 2013	Nov. 30, 2012
Cash flows from operating activities:
Net (loss) income	$ (525)	$ 1,248
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	12,285	12,161
Stock based compensation	2,423	2,375
Change in fair value of contingent consideration	1,673	197
Deferred income taxes	1,226	2,175
Change in accounts receivable allowances	312	6
Tax effect on exercise of stock options and issuance of performance shares	(146)	(504)
Other	(24)	(571)
Amortization of acquired inventory basis step-up	75	3,445
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	(103)	1,497
Inventories	(4,368)	(9,952)
Prepaid expenses and other	(358)	299
Accounts payable and accrued liabilities	3,288	(6,861)
Net cash provided by operating activities	15,758	5,515
Cash flows from investing activities:
Additions to property, plant and equipment	(7,191)	(4,787)
Acquisition of business, net of cash acquired	(4,169)	(13,908)
Acquisition of intangible and other assets	(150)	(400)
Proceeds from disposal of intangible and other assets		801
Purchases of marketable securities	(25)	(5,134)
Proceeds from sale or maturity of marketable securities	328	16,989
Net cash used in investing activities	(11,207)	(6,439)
Cash flows from financing activities:
Proceeds from issuance of long-term debt	100,000
Proceeds from borrowings on revolving credit facility	41,410
Repayment of long-term debt	(143,750)	(3,750)
Deferred financing costs on long-term debt	(677)
Payment of contingent consideration previously established in purchase accounting	(9,300)
Proceeds from exercise of stock options and employee stock purchase plan	1,133	476
Net cash used in financing activities	(11,184)	(3,274)
Effect of exchange rate changes on cash and cash equivalents	4	12
Decrease in cash and cash equivalents	(6,629)	(4,186)
Cash and cash equivalents at beginning of period	21,802	23,508
Cash and cash equivalents at end of period	15,173	19,322
Supplemental disclosure of non-cash investing and financing activities:
Contractual obligations for acquisition of intangibles and business	4,970	60,302
Contractual obligations for acquisition of fixed assets	$ 724	$ 2,509

Consolidated Statement of Stockholders' Equity - 6 months ended Nov. 30, 2013 - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Treasury Stock [Member]
Beginning Balance at May. 31, 2013	$ 526,830	$ 351	$ 500,554	$ 29,563	$ (1,534)	$ (2,104)
Beginning Balance, Shares at May. 31, 2013		35,060,351				(142,305)
Net loss	(525)			(525)
Exercise of stock options	466		466
Exercise of stock options, Shares		54,922
Tax impact of stock option activity	(146)		(146)
Purchase of common stock under ESPP	668	$ 1	667
Purchase of common stock under ESPP, Shares		71,989
Issuance of performance shares	1	$ 1
Issuance of performance shares, Shares		117,967
Stock based compensation	2,423		2,423
Other comprehensive income, net of tax	12				12
Ending Balance at Nov. 30, 2013	$ 529,729	$ 353	$ 503,964	$ 29,038	$ (1,522)	$ (2,104)
Ending Balance, Shares at Nov. 30, 2013		35,305,229				(142,305)

Consolidated Financial Statements	6 Months Ended
Consolidated Financial Statements	Nov. 30, 2013
Accounting Policies [Abstract]
Consolidated Financial Statements	NOTE A – CONSOLIDATED FINANCIAL STATEMENTS The consolidated balance sheet as of November 30, 2013, the consolidated statement of stockholders’ equity for the six months ended November 30, 2013, the consolidated statements of income, the consolidated statements of comprehensive income and the consolidated statement of cash flows for the three and six months ended November 30, 2013 and November 30, 2012 have been prepared by us without audit. The consolidated balance sheet as of May 31, 2013 was derived from audited consolidated financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to state fairly the financial position, changes in stockholders’ equity and comprehensive income, results of operations and cash flows as of and for the period ended November 30, 2013 (and for all periods presented) have been made. Certain information and footnote disclosures, normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America, have been condensed or omitted. It is suggested that these unaudited interim consolidated financial statements be read in conjunction with the financial statements and notes thereto included in the Annual Report on Form 10-K for the fiscal year ended May 31, 2013, filed by us on August 14, 2013. Our most significant accounting policies are disclosed in Note A to the consolidated financial statements included in the aforementioned Form 10-K for the fiscal year ended May 31, 2013. The results of operations in the fiscal periods ended November 30, 2013 and November 30, 2012 are not necessarily indicative of the operating results for the respective full fiscal years. The unaudited interim consolidated financial statements for the three and six months ended November 30, 2013 and November 30, 2012 include the accounts of AngioDynamics, Inc. and its wholly owned subsidiaries, RITA Medical Systems, LLC, AngioDynamics UK Limited, AngioDynamics Netherlands B.V., NM Holding Company, Inc. (Navilyst), Vortex Medical, Inc. since October 15, 2012 and Clinical Devices B.V. since August 15, 2013, (collectively, the “Company”). All intercompany balances and transactions have been eliminated. *Recent Developments* *Operational Excellence Program* On December 5, 2013, we announced a company-wide operational excellence program designed to save between $15 and $18 million during the course of the next three years. The initiative is expected to create greater efficiencies and drive business performance improvements by focusing on several key elements, including product rationalization, lean manufacturing initiatives, supply chain optimization and enterprise resource planning (ERP) implementation. The plan also incorporates the consolidation of our New York plants to establish a single manufacturing center in Glens Falls and a distribution center in Queensbury. During the course of the three-year program, it is expected that we will reduce our New York employee base by approximately 80-100 positions as a result of this plant consolidation and reorganization. *New Credit Agreement* On September 19, 2013, we entered into a Credit Agreement (the “Credit Agreement”) with the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A. and Keybank National Association as co-syndication agents, and J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and Keybank National Association as joint bookrunners and joint lead arrangers. The Credit Agreement provides for a $100 million senior secured term loan facility (“Term Facility”) and a $100 million senior secured revolving credit facility, which includes up to a $20 million sublimit for letters of credit and a $5 million sublimit for swingline loans (the “Revolving Facility”, and together with the Term Facility, the “Facilities”). The proceeds of the Term Loan and a portion of the proceeds of the Revolving Facility were used to repay our Credit Agreement (the “Existing Credit Agreement”) dated as of May 22, 2012 with the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A. and Keybank National Association as co-syndication agents, and J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and Keybank National Association as joint bookrunners and joint lead arrangers. The proceeds of the Revolving Facility may be used for general corporate purposes of AngioDynamics and its subsidiaries. The Facilities have a five year maturity. The Term Loan has a quarterly repayment schedule equal to 5%, 5%, 10%, 15% and 65% of its principal amount in years one through five. Interest on both the Term Loan and Revolver will be based on a base rate or Eurodollar rate plus an applicable margin which increases as our total leverage ratio increases, and with the base rate and Eurodollar rate having ranges of 0.50% to 1.25% and 1.50% to 2.25% respectively. After default, the interest rate may be increased by 2.0%. The Revolver will also carry a commitment fee of 0.20% to 0.35% per annum on the unused portion. Our obligations under the Facilities are unconditionally guaranteed, jointly and severally, by our material direct and indirect domestic subsidiaries (the “Guarantors”). All obligations of AngioDynamics and the Guarantors under the Facilities are secured by first priority security interests in substantially all of the assets of AngioDynamics and the Guarantors. On September 19, 2013, we borrowed $100 million under the Term Facility and approximately $41.4 million under the Revolving Facility to repay the Existing Credit Agreement. As of November 30, 2013, $98.8 and $41.4 million were outstanding under the Term Facility and Revolving Facility, respectively. The Credit Agreement includes customary representations, warranties and covenants, and acceleration, indemnity and events of default provisions, including, among other things, two financial covenants. The first financial covenant requires us to maintain, as of the end of each of our fiscal quarters, a ratio of (i) consolidated EBITDA minus consolidated capital expenditures to (ii) consolidated interest expense paid or payable in cash plus scheduled principal payments in respect of indebtedness under the Credit Agreement of not less than 1.35 to 1.00. The second financial covenant requires us to maintain, as of the end of each of our fiscal quarters, a ratio of consolidated total indebtedness to consolidated EBITDA of not greater than 3.75 to 1.00. We were in compliance with both covenants as of November 30, 2013. On September 19, 2013, we repaid all amounts owed under the Existing Credit Agreement, and as a result, the Existing Credit Agreement was terminated. Pursuant to the terms of the Existing Credit Agreement, we had the option to repay this facility at any time prior to the maturity date without penalty. *Acquisition of Clinical Devices, B.V.* On August 15, 2013 we acquired all the outstanding shares of stock of Clinical Devices, B.V., our exclusive distributor of our fluid management products in the Netherlands. The acquisition includes certain in-process research and development for a next-generation tip location technology. See Note B for further information on the acquisition. *Regulatory Matters* On May 27, 2011, we received a Warning Letter from FDA in connection with its inspection of our Queensbury, NY manufacturing facility. In the Warning Letter, FDA cited deficiencies in the response letter we provided FDA pertaining to the inspection that occurred from January 4 to January 13, 2011. The deficiencies related to our internal procedures for medical device reporting, corrections and removals and complaint handling. We responded to the Warning Letter and completed corrective and preventive actions to address the observations noted. In December 2011, we initiated a comprehensive Quality Call to Action Program to review and augment our Quality Management Systems at our Queensbury facility. To accelerate implementation of the program, we engaged a team of external regulatory and quality experts and reallocated a significant number of engineering and product development resources to support this corporate initiative. From inception of the Quality Call to Action Program through fiscal 2013, we incurred $3.2 million in direct costs associated with the program. On February 10, 2012, we received from FDA a Form 483, List of Investigational Observations, in connection with its inspection of our Queensbury facility from November 14, 2011 to February 10, 2012. The Form 483 contained 12 observations related to, among other things, our CAPA (Corrective and Preventive Action) system, MDR (Medical Device Reporting), complaint investigation, corrections and removals, acceptance criteria and training. Some of the observations contained in the Form 483 were repeat observations from the May 27, 2011 Warning Letter. On February 13, 2012, we received from FDA a Form 483 in connection with its inspection of our Fremont facility from January 12, 2012 to February 13, 2012. The Form 483 contained six observations related to, among other things, our CAPA system, design controls, risk management and training. We provided responses to FDA within 15 business days of our receipt of the Form 483s. On September 24, 2012, we received from FDA a Form 483 in connection with its subsequent inspection of our Queensbury, NY facility from September 6 to September 14, and September 19 to September 24. This re-inspection followed our response to the original Form 483 issued by FDA on February 13, 2012. The Form 483 contained 5 observations related to 510(k) decisions, complaint investigations, acceptance criteria, corrective and preventive actions and training. All but one of the observations in the Form 483 related to events that occurred before the date that we had indicated to FDA in our previous responses that our corrective and remediation activities related to our Quality Call to Action would be completed. We provided responses to FDA within 15 business days of our receipt of the Form 483. On November 28, 2012, FDA completed an inspection of our Manchester, GA facility and no Form 483 observations were issued. We will continue to work closely with FDA to resolve any outstanding issues. Unless the items raised in the previously disclosed Warning Letters and Form 483s are corrected to FDA’s satisfaction or we come to some other arrangement with FDA finally resolving such matters, we may be subject to additional regulatory or legal action, including the issuance of warning letters, injunction, seizure or recall of products, imposition of fines or penalties or operating restrictions on our facilities. Such actions could significantly disrupt our ongoing business and operations and have a material adverse impact on our financial position and operating results. *Acquisition, restructuring and other items, net* *Navilyst Acquisition Costs* The three month and six month periods ended November 30, 2013 included approximately $1.6 million and $2.8 million, respectively, in transaction and severance costs related to the Navilyst acquisition. The three month and six month periods ended November 30, 2012 included approximately $1.7 million and $3.9 million, respectively, in transaction and severance costs related to the Navilyst acquisition of May 22, 2012. These costs are included in “Acquisition, restructuring and other items, net” in the statements of income.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=28200181&loc=SL6228881-111685

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 272
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-SubTopic 15
-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 915
-SubTopic 235
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Acquisitions	6 Months Ended
Acquisitions	Nov. 30, 2013
Business Combinations [Abstract]
Acquisitions	NOTE B – ACQUISITIONS *Acquisition of Clinical Devices* On August 15, 2013 we acquired all the outstanding shares of capital stock of Clinical Devices, B.V., exclusive distributor of our fluid management products in the Netherlands. The stock purchase agreement provided for the payment of $3.7 million in cash at closing, which was subject to a working capital adjustment and $400,000 holdback, plus future earn out consideration payable in cash. Earn out consideration is based on our net sales of the fluid management products during the five quarters following the closing as well as milestone payments for achieving regulatory approvals of certain in process research and development for a next-generation tip location technology. The total estimated purchase consideration of $8.7 million includes the upfront payment and the estimated fair value of contingent consideration of $5.0 million. See Note J for additional information related to the contingent Earn out liability. Goodwill recorded as a result of the acquisition was approximately $4.3 million. Goodwill is not deductible for tax purposes. Intangible assets acquired, other than goodwill, totaled approximately $5.1 million, of which $3.6 million has been identified for in-process research and development (10-year estimated weighted average useful life), $1.4 million as customer relationships (15-year estimated weighted average useful life) and $100,000 as trademarks (5-year estimated weighted average useful life). A deferred tax liability of $1.2 million was also recorded. The acquisition has been accounted for as a purchase and, accordingly, we have included the results of operations in the financial statements effective August 15, 2013. The pro-forma effects of the acquisition on our income statement and balance sheet were not material. *Acquisition of Microsulis Medical Ltd.* On March 22, 2012, we established a strategic relationship with Microsulis Medical Ltd. (“Microsulis”), a U.K.-based company specializing in minimally-invasive, microwave ablation technology for the coagulation of soft tissue. On February 1, 2013, we completed the acquisition of certain assets of Microsulis, which we have accounted for as a business combination, for cash payments at closing totaling $10.0 million, which is subject to a working capital adjustment, a $5.0 million payment due on December 31, 2013 and potential additional cash consideration payable upon performance over the next nine years. We also assumed $1.6 million of liabilities. The total estimated purchase consideration of $33.6 million includes the initial investment of $5.0 million, closing payments totaling $10.5 million, a $5.0 million payment due on December 31, 2013 and the estimated fair value of contingent consideration (Earn out) of $13.2 million. The $5.0 million payment was made on December 31, 2013. The estimated fair value of contingent consideration is based on projected net sales over the nine year period following the closing. The amount of the Earn out consideration that could be paid on net sales is not limited. See Note J for additional information related to the contingent Earn out liability. The estimated purchase consideration exceeds the fair value of the acquired net assets by $19.3 million and was recorded as goodwill. Goodwill is deductible for tax purposes. Intangible assets are being amortized over their estimated useful lives of which range from 10 to 15 years. During the three and six month periods ended November 30, 2013, we incurred acquisition related costs of $0 and $60 thousand, respectively, which were expensed to “Acquisition, restructuring and other items, net” in the statement of income. *Acquisition of Vortex Medical, Inc.* On October 15, 2012, we acquired all the outstanding capital stock of Vortex Medical, Inc., a privately-held company focused on the development and commercialization of medical devices for venous drainage and the removal of thrombus, or blood clots, from occluded blood vessels. Vortex’s principal product is the AngioVac ^® system, which includes the AngioVac Cannula and Circuit. The AngioVac Cannula has a proprietary balloon-actuated, expandable, funnel-shaped distal tip that enhances flow, prevents clogging of the cannula and facilitates en bloc, or whole removal of undesirable intravascular material. Both the AngioVac Cannula and Circuit are FDA-cleared for use during extracorporeal bypass for up to 6 hours. CE Mark approval was received in December 2013. The total estimated purchase consideration of $75.3 million included the upfront payment of $15.1 million and the estimated fair value of contingent consideration of $60.3 million, $40 million of which is guaranteed. The estimated fair value of contingent consideration is based on projected AngioVac net sales in the ten year period following the closing. The amount of the Earn out consideration that could be paid on AngioVac net sales is not limited. See Note J for additional information related to the contingent Earn out liability. The purchase consideration exceeded the fair value of the acquired net assets by $29.5 million and was recorded as goodwill. Goodwill is not deductible for tax purposes. Core technologies are being amortized over their estimated useful lives of approximately 15 years as revenues are earned from the sales of the related products.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6996-128479

+ Details

Inventories

6 Months Ended

Nov. 30, 2013

Inventory Disclosure [Abstract]

Inventories

NOTE C – INVENTORIES

Inventories are stated at lower of cost (at standard cost which approximates the first-in, first-out method) or market. Inventories consist of the following:


	Nov 30, 2013		May 31, 2013
	(in thousands)
Raw materials	$	24,287	$	18,362
Work in process		11,557		11,006
Finished goods		24,208		25,694

Inventories	$	60,052	$	55,062

Goodwill and Intangible Assets

6 Months Ended

Nov. 30, 2013

Goodwill And Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

NOTE D – GOODWILL AND INTANGIBLE ASSETS

Intangible assets other than goodwill and indefinite lived intangible assets are amortized over their estimated useful lives, which range between three and fifteen years, on either a straight-line basis over the expected period of benefit or as revenues are earned from the sales of the related products. We periodically review the estimated useful lives of our intangible assets and review such assets for impairment whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Our determination of impairment is based on estimates of future cash flows. If an intangible asset is considered to be impaired, the amount of the impairment will equal the excess of the carrying value over the fair value of the asset.

Goodwill and intangible assets that have indefinite useful lives are not amortized, but rather, are tested for impairment annually or more frequently if impairment indicators arise. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. Goodwill and intangible assets have been recorded at either incurred or allocated costs. Allocated costs were based on respective fair market values at the date of acquisition.

For goodwill, the impairment test requires a comparison of the estimated fair value of the reporting unit to which the goodwill is assigned to the sum of the carrying value of the assets and liabilities of that unit. If the sum of the carrying value of the assets and liabilities of a reporting unit exceeds the fair value of the reporting unit, the carrying value of the reporting unit’s goodwill is reduced to its implied fair value through an adjustment to the goodwill balance, resulting in an impairment charge. Our determination of impairment is based on estimates of future cash flows.

To determine fair value, we considered two market-based approaches and an income approach. Under the market-based approaches, we utilized information regarding our own as well as publicly available industry information to determine earnings multiples and sales multiples. Under the income approach, we determined fair value based on estimated future cash flows of the reporting unit, discounted by an estimated weighted-average cost of capital, which reflects the overall level of inherent risk of a reporting unit and the rate of return an outside investor would expect to earn. We determined the discounted cash flow as the best indicator to determine fair value.

Determining the fair value of a reporting unit is judgmental in nature and requires the use of significant estimates and assumptions, including revenue growth rates, operating margins, discount rates and future market conditions, among others. These assumptions are highly sensitive and changes in these estimates could result in impairment. Solely for purposes of establishing inputs for the fair value calculations, we assumed that the current economic conditions would continue through fiscal year 2014, followed by a recovery thereafter. In addition, we applied gross margin assumptions consistent with our historical trends at various revenue levels and used an EBITDA exit multiple of 6.0 to calculate the terminal value of the reporting unit. In addition, we used a discount rate of 13.5% to calculate the fair value of our reporting unit.

We completed our annual goodwill impairment test as of December 31, 2012. At December 31, 2012, our reporting unit is the same as our reportable segment. Our assessment of goodwill impairment indicated that the fair value of our reporting unit exceeded its carrying value and therefore goodwill was not impaired. The fair value of our reporting unit exceeded its carrying value by 5%. The fair value of the reporting unit was reconciled to our current stock market capitalization plus an estimated control premium of approximately 60% as of December 31, 2012.

Since early November 2008, our stock market capitalization has at times been lower than our shareholders’ equity or book value. However, our reporting unit has continued to generate significant cash flows from operations, and we expect to continue to do so in fiscal 2014 and beyond. Furthermore, we believe that a reasonable potential buyer would offer a control premium for our business that would adequately cover the difference between our stock market capitalization and our book value.

We also completed our annual indefinite lived asset (NAMIC trademark) test as of December 31, 2012 using the income approach to determine fair value. Our assessment of the NAMIC trademark indicated that the fair value exceeded the carrying value and therefore the asset was not impaired.

Even though we determined that there was no goodwill impairment as of December 31, 2012, the future occurrence of a potential indicator of impairment, such as a significant adverse change in legal factors or business climate, an adverse action or assessment by a regulator, unanticipated competition, a material negative change in relationships with significant customers, strategic decisions made in response to economic or competitive conditions, loss of key personnel or a more-likely-than-not expectation that the reporting unit or a significant portion of the reporting unit will be sold or disposed of, would require an interim assessment for the reporting unit prior to the next required annual assessment as of December 31, 2013.

It is not possible at this time to determine if any such future impairment charge would result or, if it does, whether such charge would be material. Events that could, in the future, result in impairment include, but are not limited to, declining sales for a significant product or in a significant geographic region.

Adjustments to goodwill for the six months ended November 30, 2013 are as follows (in thousands):


Balance, May 31, 2013	$	355,458
Acquisition of Clinical Devices B.V.		4,278

Balance, November 30, 2013	$	359,736

The above change in the carrying value of goodwill is the result of the acquisition of Clinical Devices, B.V. as discussed in Note B.

The balances of intangible assets are as follows:


	November 30, 2013
	Gross carrying value		Accumulated amortization			Net carrying value		Weighted avg useful life
			(in thousands)					(years)
Product technologies	$	149,111	$	(28,623	)	$	120,488		10.3
Customer relationships		86,640		(34,593	)		52,047		11.9
Trademark-NAMIC		28,600		—			28,600		Indefinite
Licenses		7,540		(4,949	)		2,591		7.5
Trademarks		6,345		(1,476	)		4,869		8.0
In-process R&D acquired		3,600		—			3,600		Indefinite
Distributor relationships		900		(900	)		—		3.0

	$	282,736	$	(70,541	)	$	212,195


	May 31, 2013
	Gross carrying value		Accumulated amortization			Net carrying value		Weighted avg useful life
			(in thousands)					(years)
Product technologies	$	150,181	$	(24,835	)	$	125,346		10.6
Customer relationships		84,479		(30,595	)		53,884		14.8
Trademark-NAMIC		28,600		—			28,600		Indefinite
Licenses		6,302		(4,501	)		1,801		9.0
Trademarks		6,275		(1,058	)		5,217		9.9
Distributor relationships		900		(900	)		—		3.0

	$	276,737	$	(61,889	)	$	214,848

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Accrued Liabilities

6 Months Ended

Nov. 30, 2013

Payables And Accruals [Abstract]

Accrued Liabilities

NOTE E – ACCRUED LIABILITIES

Accrued liabilities consist of the following:


	Nov 30, 2013		May 31, 2013
	(in thousands)
Payroll and related expenses	$	6,217	$	6,491
Royalties		2,084		2,034
Income taxes payable		741		—
Deferred revenue		1,616		1,573
Accrued severance		1,200		1,602
Sales and franchise taxes		1,329		1,047
Interest rate swap liability		725		523
Other		3,618		3,156

Total	$	17,530	$	16,426

Long Term Debt	6 Months Ended
Long Term Debt	Nov. 30, 2013
Debt Disclosure [Abstract]
Long Term Debt	NOTE F – LONG TERM DEBT New Credit Agreement On September 19, 2013, we entered into a Credit Agreement (the “Credit Agreement”) with the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A. and Keybank National Association as co-syndication agents, and J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and Keybank National Association as joint bookrunners and joint lead arrangers. The Credit Agreement provides for a $100 million senior secured term loan facility (“Term Loan”) and a $100 million senior secured revolving credit facility, which includes up to a $20 million sublimit for letters of credit and a $5 million sublimit for swingline loans (the “Revolving Facility”, and together with the TermLoan, the “Facilities”). The proceeds of the Term Loan and a portion of the proceeds of the Revolving Facility were used to repay our Credit Agreement (the “Existing Credit Agreement”) dated as of May 22, 2012 with the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A. and Keybank National Association as co-syndication agents, and J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and Keybank National Association as joint bookrunners and joint lead arrangers. The proceeds of the Revolving Facility may be used for general corporate purposes of AngioDynamics and its subsidiaries. The Facilities have a five year maturity. The Term Loan has a quarterly repayment schedule equal to 5%, 5%, 10%, 15% and 65% of its principal amount in years one through five. Interest on both the Term Loan and Revolving Facility will be based on a base rate or Eurodollar rate plus an applicable margin which increases as our total leverage ratio increases, and with the base rate and Eurodollar rate having ranges of 0.50% to 1.25% and 1.50% to 2.25% respectively. After default, the interest rate may be increased by 2.0%. The Revolving Facility will also carry a commitment fee of 0.20% to 0.35% per annum on the unused portion. Our obligations under the Facilities are unconditionally guaranteed, jointly and severally, by our material direct and indirect domestic subsidiaries (the “Guarantors”). All obligations of AngioDynamics and the Guarantors under the Facilities are secured by first priority security interests in substantially all of the assets of AngioDynamics and the Guarantors. In June 2012, we entered in an interest rate swap agreement, (the “Swap Agreement”), with an initial notional amount of $100 million, to limit the effect of rising of interest rates. The Swap Agreement, which qualified for hedge accounting under authoritative guidance, was a contract to exchange floating interest rate payments for fixed interest rate payments on the outstanding balance of the loan over the life of the agreement without the exchange of the underlying notional amounts. The Swap Agreement provides for a fixed rate of 0.74% above the applicable rate provided for in the Credit Agreement. On September 19, 2013, we borrowed $100 million under the Term Facility and approximately $41.4 million under the Revolving Facility to repay the Existing Credit Agreement. As of November 30, 2013, $98.8 million and $41.4 million were outstanding under the Term Facility and Revolving Facility, respectively. The Credit Agreement includes customary representations, warranties and covenants, and acceleration, indemnity and events of default provisions, including, among other things, two financial covenants. The first financial covenant requires us to maintain, as of the end of each of our fiscal quarters, a ratio of (i) consolidated EBITDA minus consolidated capital expenditures to (ii) consolidated interest expense paid or payable in cash plus scheduled principal payments in respect of indebtedness under the Credit Agreement of not less than 1.35 to 1.00. The second financial covenant requires us to maintain, as of the end of each of our fiscal quarters, a ratio of consolidated total indebtedness to consolidated EBITDA of not greater than 3.75 to 1.00. We were in compliance with both covenants as of November 30, 2013. On September 19, 2013, we repaid all amounts owed under the Existing Credit Agreement, and as a result, the Existing Credit Agreement was terminated. Pursuant to the terms of the Existing Credit Agreement, we had the option to repay this facility at any time prior to the maturity date without penalty.

Income Taxes	6 Months Ended
Income Taxes	Nov. 30, 2013
Income Tax Disclosure [Abstract]
Income Taxes	NOTE G – INCOME TAXES Our effective tax rate was 15% for the second fiscal quarter of 2014 compared with 37% for the prior year period. The current quarter reflects a seven month benefit from the R&D tax credit that expired on December 31, 2013 and a benefit from lower tax rates in foreign jurisdictions in which we operate, offset by non-deductible interest expense related to contingent payments. Additionally during the second fiscal quarter of 2014, our APIC pool, which has been historically reduced when share-based compensation cost previously recognized by us was greater than the deduction allowed for income tax purposes based on the price of our common stock on the date of exercise or vesting, was fully depleted. This depletion resulted in a discrete tax expense which caused our tax benefit related to the loss for the quarter to be reported as a net tax expense. The prior year quarter was affected by a reduction in the Domestic Production Activities Deduction caused by reduced taxable income, the tax impact of non-deductible costs related to the acquisition of Vortex and a tax benefit related to the use of fully reserved capital loss carryforwards made possible by the gain on sale of our PDT laser product line. Our effective tax rate was a 28% benefit for the first six months of fiscal 2014 compared with 37% expense for the prior year period. The current period reflects a seven month benefit from the R&D tax credit that expired on December 31, 2013 and a benefit from lower tax rates in foreign jurisdictions in which we operate, offset by non-deductible interest expense related to contingent payments. Additionally during the 2014 period, our APIC pool, which has been historically reduced when share-based compensation cost previously recognized by us was greater than the deduction allowed for income tax purposes based on the price of our common stock on the date of exercise or vesting, was fully depleted. The prior period is affected by a reduction in the Domestic Production Activities Deduction caused by reduced taxable income, the tax impact of non-deductible costs related to the acquisition of Vortex and a tax benefit related to the use of fully reserved capital loss carryforwards made possible by the gain on sale of our PDT laser product line. The prior year period reflects a benefit from the R&D tax credit which expired December 31, 2011 and was retroactively reinstated during fiscal year 2013.

Earnings Per Common Share

6 Months Ended

Nov. 30, 2013

Earnings Per Share [Abstract]

Earnings Per Common Share

NOTE H – EARNINGS PER COMMON SHARE

Basic earnings per share are based on the weighted average number of common shares outstanding without consideration of potential common stock. Diluted earnings per share further includes the dilutive effect of potential common stock consisting of stock options and restricted stock units, provided that the inclusion of such securities is not antidilutive. Due to a reported net loss for both the second fiscal quarter of 2014 and fiscal year to date 2014 , our basic and diluted earnings per share calculations are identical for those periods.

The following table sets forth the reconciliation of the weighted-average number of common shares (in thousands):


	Three Months Ended				Six Months Ended
	Nov 30, 2013		Nov 30, 2012		Nov 30, 2013		Nov 30, 2012
Basic		35,132		34,827		35,041		34,765
Effect of dilutive securities		0		484		0		514

Diluted		35,132		35,311		35,041		35,279

Excluded from the calculation of diluted earnings per common share were options and restricted stock awards issued to employees and non-employees to purchase 2.3 million and 2.7 million shares of common stock for the three months and six months ended November 30, 2013, as their inclusion would be antidilutive. For the three and six month period ended November 30, 2012, options and restricted stock awards issued to employees and non-employees to purchase 3.2 million and 3.0 million shares of common stock were also excluded as their inclusion would have been antidilutive.

Segment and Geographic Information

6 Months Ended

Nov. 30, 2013

Segment Reporting [Abstract]

Segment and Geographic Information

NOTE I – SEGMENT AND GEOGRAPHIC INFORMATION

We consider our business to be a single operating segment entity – the development, manufacture and sale on a global basis of medical devices for vascular access, surgery, peripheral vascular disease and oncology. Our chief operating decision maker (CEO) evaluates the various global product portfolios on a net sales basis. Executives reporting to the CEO include those responsible for operations and supply chain management, research and development, sales, franchise marketing and certain corporate functions. The CEO evaluates profitability, investment and cash flow metrics on a consolidated worldwide basis due to shared infrastructure and resources.

Net sales by product category are summarized below (in thousands):


	Three Months Ended				Six Months Ended
	Nov 30, 2013		Nov 30, 2012		Nov 30, 2013		Nov 30, 2012
Net sales
Peripheral Vascular	$	48,860	$	45,766	$	94,340	$	89,060
Vascular Access		25,571		26,712		50,854		53,342
Oncology/Surgery		12,557		12,006		23,724		23,239
Supply Agreement		1,628		2,523		3,277		4,782

Total	$	88,616	$	87,007	$	172,195	$	170,423

Net sales for geographic areas, based on external customer location, are summarized below (in thousands):


	Three Months Ended				Six Months Ended
	Nov 30, 2013		Nov 30, 2012		Nov 30, 2013		Nov 30, 2012
Net Sales
United States	$	69,530	$	67,129	$	136,632	$	132,898
International		17,458		17,355		32,286		32,743
Supply Agreement		1,628		2,523		3,277		4,782

Total	$	88,616	$	87,007	$	172,195	$	170,423

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

+ Details

Fair Value

6 Months Ended

Nov. 30, 2013

Fair Value Disclosures [Abstract]

Fair Value

NOTE J – FAIR VALUE

Our financial instruments include cash and cash equivalents, accounts receivable, marketable securities, accounts payable, interest rate swap agreement and contingent earn outs related to the acquisitions of Vortex, Microsulis and Clinical Devices. The carrying amount of cash and cash equivalents, accounts receivable, marketable securities and accounts payable approximates fair value due to the immediate or short-term maturities. The interest rate swap agreement has been recorded at its fair value based on a valuation received from an independent third party. Marketable securities, with the exception of auction rate securities, are carried at their fair value as determined by quoted market prices. The contingent earn out has been recorded at fair value using the income approach.

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. This policy establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value which are provided in the table below.


Level 1		Quoted prices in active markets for identical assets or liabilities. Level 1 assets include bank time deposits, money market funds, mutual funds and U.S. Treasury securities that are traded in an active exchange market.

Level 2		Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 2 assets include US government securities and corporate bonds. When quoted market prices are unobservable, we obtain pricing information from an independent pricing vendor. The pricing vendor uses various pricing models for each asset class that are consistent with what other market participants would use. The inputs and assumptions to the model of the pricing vendor are derived from market observable sources including: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, benchmark securities, bids, offers, and other market-related data. Since many fixed income securities do not trade on a daily basis, the methodology of the pricing vendor uses available information as applicable such as benchmark curves, benchmarking of like securities, sector groupings, and matrix pricing. The pricing vendor considers all available market observable inputs in determining the evaluation for a security. Thus, certain securities may not be priced using quoted prices, but rather determined from market observable information. These investments are included in Level 2 and primarily comprise our portfolio of corporate and government fixed income securities. Additionally included in Level 2 are interest rate swap agreements which are valued using a mid-market valuation model.

Level 3		Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. This category currently includes the auction rate securities where independent pricing information was not able to be obtained and the contingent Earn out related to the acquisition of Vortex, Microsulis and Clinical Devices. Our investments in auction-rate securities were classified as Level 3 as quoted prices were unavailable since these auction rate securities issued by New York state and local government authorities failed auction. Due to limited market information, we utilized a discounted cash flow (“DCF”) model to derive an estimate of fair value for all periods presented. The assumptions used in preparing the DCF model included estimates with respect to the amount and timing of future interest and principal payments, forward projections of the interest rate benchmarks, the probability of full repayment of the principal considering the credit quality and guarantees in place, and the rate of return required by investors to own such securities given the current liquidity risk associated with auction-rate securities. The contingent earn outs were valued utilizing a discounted cash flow method as detailed below.

The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis (in thousands):


	Fair Value Measurements using inputs considered as:						Fair Value at November 30, 2013
	Fair Value Measurements using inputs considered as:
	Level 1		Level 2		Level 3
Financial Assets
Cash equivalents
Money market funds	$	420	$	—	$	—	$	420

Total	$	420	$	—	$	—	$	420

Marketable securities
U.S. government agency obligations	$	—	$	—	$	1,850	$	1,850

Total		—		—		1,850		1,850

Total Financial Assets	$	420	$	—	$	1,850	$	2,270


Financial Liabilities
Interest rate swap agreements	$	—	$	725	$	—	$	725
Contingent liability for acquisition earn out		—		—		72,392		72,392

Total Financial Liabilities	$	—	$	725	$	72,392	$	73,117


	Fair Value Measurements using inputs considered as:						Fair Value at May 31, 2013
	Fair Value Measurements using inputs considered as:
	Level 1		Level 2		Level 3
Financial Assets
Cash equivalents
Money market funds	$	114	$	—	$	—	$	114

Total	$	114	$	—	$	—	$	114

Marketable securities
Corporate bond securities	$	—	$	303	$	—	$	303
U.S. government agency obligations		—		—		1,850		1,850

Total		—		303		1,850		2,153

Total Financial Assets	$	114	$	303	$	1,850	$	2,267


Financial Liabilities
Interest rate swap agreements	$	—	$	522	$	—	$	522
Contingent liability for acquisition earn out						75,049		75,049

Total Financial Liabilities	$	—	$	522	$	75,049	$	75,571

There were no significant transfers in and out of Level 1, 2 and 3 measurements for the three months ended November 30, 2013.

The components of Level 3 fair value instruments as of November 30, 2013 are shown below (in thousands):


	Financial Assets		Financial Liabilities
	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)		Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Balance, May 31, 2013	$	1,850	$	75,049
Total gains or losses (realized/unrealized):		—		—
Included in earnings		—		1,673
Included in other comprehensive income		—		—
Purchases, issuances and settlements		—		(9,300	)
Transfers in and/or (out) of Level 3		—		—
Contingent consideration - Clinical Devices		—		4,970

Balance, November 30, 2013	$	1,850	$	72,392

Contingent Liability for Acquisition Earn Outs

Certain of our business combinations involve the potential for the payment of future contingent consideration upon the achievement of certain product development milestones and/or various other favorable operating conditions. Payment of the additional consideration is generally contingent on the acquired company reaching certain performance milestones, including attaining specified revenue levels or achieving product development targets. Contingent consideration is recorded at the estimated fair value of the contingent milestone payments on the acquisition date. The fair value of the contingent milestone consideration is remeasured at the estimated fair value at each reporting period with the change in fair value recognized as income or expense within acquisition-related items in the condensed consolidated statements of earnings. We measure the initial liability and remeasure the liability on a recurring basis using Level 3 inputs as defined under authoritative guidance for fair value measurements.

Contingent consideration liabilities will be remeasured to fair value each reporting period using projected net sales, discount rates, probabilities of payment and projected payment dates. Projected contingent payment amounts are discounted back to the current period using a discounted cash flow model. Projected net sales are based on our internal projections and extensive analysis of the target market and the sales potential. Increases in projected net sales and probabilities of payment may result in higher fair value measurements in the future. Increases in discount rates and the projected time to payment may result in lower fair value measurements in the future. Increases or decreases in any valuation inputs in isolation may result in a significantly lower or higher fair value measurement in the future.

The recurring Level 3 fair value measurements of the contingent consideration liability related to the Vortex, Microsulis and Clinical Devices acquisitions include the following significant unobservable inputs ($ in millions):


	Fair value at Nov 30, 2013		Valuation Technique	Unobservable Input	Range
Revenue based payments	$	68.1	Discounted	Discount rate	4%-10%
			cash flow	Probability of payment	75-100%
				Projected fiscal year of payment	2014-2022

Milestone based payments	$	4.3	Discounted	Discount rate	16%-20%
			cash flow	Probability of payment	75-100%
				Projected fiscal year of payment	2014-2015

Total	$	72.4

At November 30, 2013, the estimated potential amount of undiscounted future contingent consideration that we expect to pay as a result of all completed acquisitions is approximately $91.7 million. The milestones associated with the contingent consideration must be reached in future periods ranging from fiscal years 2014 to 2022 in order for the consideration to be paid.

The fair value of contingent milestone payments associated with the acquisitions was remeasured as of November 30, 2013 and $60.2 million was reflected in “Contingent consideration, net of current portion” and $12.2 million was reflected in “Current portion of contingent consideration” on the condensed consolidated balance sheet.

The following table provides a reconciliation of the beginning and ending balances of contingent milestone payments associated with the Vortex, Microsulis and Clinical Devices acquisitions measured at fair value that used significant unobservable inputs (Level 3) (in thousands):


Beginning balance - May 31, 2013	$	75.0
Purchase price contingent consideration		5.0
Contingent payments		(9.3	)
Change in fair value of contingent consideration		1.7

Ending balance - November 30, 2013	$	72.4

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Marketable Securities

6 Months Ended

Nov. 30, 2013

Investments Debt And Equity Securities [Abstract]

Marketable Securities

NOTE K – MARKETABLE SECURITIES

Marketable securities, which are principally government agency bonds, auction rate investments and corporate commercial paper, are classified as “available-for-sale securities” in accordance with authoritative guidance issued by FASB and are reported at fair value, with unrealized gains and losses excluded from operations and reported as accumulated other comprehensive income (loss), net of the related tax effects, in stockholders’ equity. Cost is determined using the specific identification method. We hold investments in auction rate securities in order to generate higher than typical money market rate investment returns. Auction rate securities typically are high credit quality, generally achieved with municipal bond insurance. Credit risks are eased by the historical track record of bond insurers, which back a majority of this market. Sell orders for any security traded through an auction process could exceed bids and, in such cases, the auction fails and we may be unable to liquidate our position in the securities in the near term. As of November 30, 2013 and May 31, 2013, we had $1.85 million in investments in two auction rate securities issued by New York state and local government authorities that failed auctions. The authorities are current in their interest payments on the securities.

Marketable securities as of November 30, 2013 consisted of the following:


	Amortized cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
	(in thousands)
Available-for-sales securities
U.S. government agency obligations	$	1,850	$	—	$	—	$	1,850

	$	1,850	$	—	$	—	$	1,850

Marketable securities as of May 31, 2013 consisted of the following:


	Amortized cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
	(in thousands)
Available-for-sales securities
U.S. government agency obligations	$	1,850	$	—	$	—	$	1,850
Corporate bond securities		303		—		—		303

	$	2,153	$	—	$	—	$	2,153

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References + Details

Litigation	6 Months Ended
Litigation	Nov. 30, 2013
Commitments And Contingencies Disclosure [Abstract]
Litigation	NOTE L – LITIGATION *AngioDynamics v. biolitec* On January 2, 2008, we commenced an action in the United States District Court for the Northern District of New York entitled AngioDynamics, Inc. v. biolitec, Inc. In this action, we sought judgment against biolitec for defense and indemnification in two lawsuits which we previously settled. Our claims arise out of a Supply and Distribution Agreement (“SDA”) entered into with biolitec on April 1, 2002. On September 27, 2011, the U.S. District Court granted key portions of our motion for summary judgment in our legal case against biolitec. The Court also dismissed biolitec’s counterclaims against us. The court denied one portion of our summary judgment motion, which sought to recover additional costs from biolitec, leaving this for adjudication at trial. On November 8, 2012, the Court granted partial judgment to us in the amount of $23.2 million. Biolitec appealed this judgment. On August 23, 2013, the U.S. Court of Appeals for the Second Circuit dismissed biolitec’s appeal. In October 2009, we commenced an action in the United States District Court for the District of Massachusetts entitled AngioDynamics, Inc. v. biolitec AG and Wolfgang Neuberger. The Complaint in this action was amended in March 2010. This action seeks to recover against biolitec, Inc.’s parent entities and CEO for tortiously interfering with biolitec, Inc.’s contractual obligation to defend and indemnify us, and also seeks to pierce the corporate veil of biolitec, Inc. and to invalidate certain alleged fraudulent transfers in order to hold biolitec, Inc.’s parent entities jointly and severally liable for the alleged breach of the SDA. On September 13, 2012, the Massachusetts Court granted our request for a preliminary injunction prohibiting the downstream merger of biolitec AG with its Austrian subsidiary. On April 1, 2013, the U.S. Court of Appeals for the First Circuit affirmed the preliminary injunction. As of November 29, 2013, cross-motions for summary judgment were pending before the District Court. In August 29, 2013, we became co-plaintiffs in an adversary proceeding in the United States Bankruptcy Court for the District of New Jersey entitled Cyganowski, Trustee, et al. v. Biolitec U.S., Inc., et al. In this action, we assert claims of conversion, unjust enrichment, tortious interference, and unfair competition against various biolitec entities for alleged violation of Bankruptcy Court settlement and sale orders under which we acquired certain assets of Biolitec, Inc. On September 3, 2013, we, along with our co-plaintiff, obtained a temporary restraining order against the defendants in this action. *C.R. Bard, Inc. v. AngioDynamics, Inc.* On January 11, 2012, C.R. Bard, Inc. filed a suit in the United States District Court of Utah claiming certain of our implantable port products infringe on patents held by Bard. Bard is seeking unspecified damages and other relief. The Court denied Bard’s motion for pre-trial consolidation with separate actions it filed on the same day against Medical Components, Inc. and Smiths Medical ASD, Inc., but has asked for supplemental briefing on the issue of whether to conduct a common Markman hearing. We filed petitions for reexamination in the US Patent and Trademark Office which seek to invalidate all three patents asserted in the litigation. Our petitions have been granted and 40 of 41 patent claims have been and remain rejected. The Patent Office has issued a Final Rejection of all the claims subject to reexamination and Bard has filed notices of appeal. The case has been stayed pending final resolution of the PTO process. We believe these claims are without merit and intend to defend them vigorously. We have not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable. *Cardinal Health v. Navilyst Medical, Inc.* On December 21, 2011, Cardinal Health Canada 204, Inc. (“Cardinal Health”) filed a demand for arbitration pursuant to the terms of the International Distributorship Agreement entered into as of November 1, 2008 between Navilyst and Cardinal Health. Cardinal Health claims that it is entitled to damages based on Navilyst’s decision to terminate the International Distributorship Agreement. On September 27, 2013, the parties agreed to a Stipulation of Dismissal With Prejudice, and the case is now terminated. *Joseph Pierre v. AngioDynamics, Inc.* In July 2011, a former employee dual-filed a complaint with the New York State Division of Human Rights and the Equal Employment Opportunity Commission, entitled Joseph Pierre v. AngioDynamics, Inc. In this action, the former employee is alleging discrimination due to his status as an African-American, in light of him being reassigned to another project. At the conclusion of its investigation, the Division issued a finding of “no probable cause” on January 6, 2012 and dismissed the complaint. The complainant did not appeal the decision to preserve his New York Human Rights Law claims. On February 22, 2012, the Equal Employment Opportunity Commission issued its determination adopting the decision of the Division and dismissing the charge. The complainant filed a federal claim following the EEOC’s decision in the United States District Court for the Northern District of New York on May 21, 2012. This complaint makes the same allegations of discrimination, and alleges causes of action under Title VII of the Civil Rights Act and 42 U.S.C. 1981. We believe these claims are without merit but have reached a settlement agreement and filed a stipulation of discontinuance with the court. The settlement will have no impact on our financial condition or results of operations. We are party to other legal actions that arise in the ordinary course of business. We believe that any liability resulting from any currently pending litigation will not, individually or in the aggregate, have a material adverse effect on our business, financial condition, results of operations, or cash flows.

Recently Issued Accounting Pronouncements	6 Months Ended
Recently Issued Accounting Pronouncements	Nov. 30, 2013
Accounting Changes And Error Corrections [Abstract]
Recently Issued Accounting Pronouncements	NOTE M – RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS In July 2012, the FASB updated the accounting guidance related to testing indefinite-lived intangible assets for impairment. This update permits an entity to first make a qualitative assessment of whether it is more likely than not that an indefinite-lived intangible asset is impaired as a basis for determining whether it is necessary to perform the quantitative impairment test. An entity is not required to calculate the fair value of an indefinite-lived intangible asset and perform the quantitative impairment test unless the entity determines that it is more likely than not that the asset is impaired. The more-likely-than—not threshold is defined as having a likelihood of more than 50%. This update is effective for annual and interim impairment tests performed in fiscal years beginning after September 15, 2012 (our fiscal year 2014) however early adoption is permitted, provided that the entity has not yet performed its annual impairment test or issued its financial statements. The adoption did not have a material impact on our financial statements. In December 2011 and January 2013, the FASB issued new accounting guidance related to disclosures on offsetting assets and liabilities on the balance sheet. The newly issued accounting standard requires an entity to disclose both gross and net information about instruments and transactions executed under a master netting, or similar, arrangement and was issued to enable users of financial statements to understand the effects or potential effects of those arrangements on its financial position. This guidance is required to be applied retrospectively and is effective for fiscal years beginning on or after January 1, 2013 (our fiscal year 2014). Since the guidance only impacts disclosure requirements, its adoption did not have a material impact on our consolidated financial statements. In February 2013, the FASB expanded the disclosure requirements related to changes in accumulated other comprehensive income (AOCI). The new guidance requires disclosure of the amount of income (or loss) reclassified out of AOCI to each respective line item on the statement of income where net income is presented. The guidance allows disclosure of the reclassification either in the notes to the financial statements or parenthetically on the face of the financial statements. This requirement is effective for reporting periods beginning after December 15, 2012 (fourth quarter of our fiscal year 2013). Since the guidance only impacts disclosure requirements, its adoption did not have a material impact on our consolidated financial statements. In July 2013, the FASB issued guidance related to the presentation of certain tax information. This new pronouncement provides explicit guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, or similar tax loss, or a tax credit carryforward exists. This pronouncement is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2013 (our fiscal year 2015). Since the guidance only impacts presentation requirements, its adoption will not have a material impact on our consolidated financial statements.

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6510796

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6372559&loc=d3e765-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6372559&loc=d3e725-108305

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 01
-Paragraph b
-Subparagraph 6
-Article 10

+ Details

Subsequent Events	6 Months Ended
Subsequent Events	Nov. 30, 2013
Subsequent Events [Abstract]
Subsequent Events	NOTE N – SUBSEQUENT EVENTS *Operational Excellence Program* On December 5, 2013, we announced a company-wide operational excellence program designed to save between $15 and $18 million during the course of the next three years. The initiative is expected to create greater efficiencies and drive business performance improvements by focusing on several key elements, including product rationalization, lean manufacturing initiatives, supply chain optimization and enterprise resource planning (ERP) implementation. The plan also incorporates the consolidation of our New York plants to establish a single manufacturing center in Glens Falls and a distribution center in Queensbury. During the course of the three-year program, it is expected that we will reduce our New York employee base by approximately 80-100 positions as a result of this plant consolidation and reorganization.

Recently Issued Accounting Pronouncements (Policies)	6 Months Ended
Recently Issued Accounting Pronouncements (Policies)	Nov. 30, 2013
Accounting Changes And Error Corrections [Abstract]
Indefinite-Lived Intangible Assets Impairment	In July 2012, the FASB updated the accounting guidance related to testing indefinite-lived intangible assets for impairment. This update permits an entity to first make a qualitative assessment of whether it is more likely than not that an indefinite-lived intangible asset is impaired as a basis for determining whether it is necessary to perform the quantitative impairment test. An entity is not required to calculate the fair value of an indefinite-lived intangible asset and perform the quantitative impairment test unless the entity determines that it is more likely than not that the asset is impaired. The more-likely-than—not threshold is defined as having a likelihood of more than 50%. This update is effective for annual and interim impairment tests performed in fiscal years beginning after September 15, 2012 (our fiscal year 2014) however early adoption is permitted, provided that the entity has not yet performed its annual impairment test or issued its financial statements. The adoption did not have a material impact on our financial statements.
Offsetting Assets and Liabilities	In December 2011 and January 2013, the FASB issued new accounting guidance related to disclosures on offsetting assets and liabilities on the balance sheet. The newly issued accounting standard requires an entity to disclose both gross and net information about instruments and transactions executed under a master netting, or similar, arrangement and was issued to enable users of financial statements to understand the effects or potential effects of those arrangements on its financial position. This guidance is required to be applied retrospectively and is effective for fiscal years beginning on or after January 1, 2013 (our fiscal year 2014). Since the guidance only impacts disclosure requirements, its adoption did not have a material impact on our consolidated financial statements.
Changes in Accumulated Other Comprehensive Income	In February 2013, the FASB expanded the disclosure requirements related to changes in accumulated other comprehensive income (AOCI). The new guidance requires disclosure of the amount of income (or loss) reclassified out of AOCI to each respective line item on the statement of income where net income is presented. The guidance allows disclosure of the reclassification either in the notes to the financial statements or parenthetically on the face of the financial statements. This requirement is effective for reporting periods beginning after December 15, 2012 (fourth quarter of our fiscal year 2013). Since the guidance only impacts disclosure requirements, its adoption did not have a material impact on our consolidated financial statements.
Income Taxes	In July 2013, the FASB issued guidance related to the presentation of certain tax information. This new pronouncement provides explicit guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, or similar tax loss, or a tax credit carryforward exists. This pronouncement is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2013 (our fiscal year 2015). Since the guidance only impacts presentation requirements, its adoption will not have a material impact on our consolidated financial statements.

Inventories (Tables)

6 Months Ended

Nov. 30, 2013

Inventory Disclosure [Abstract]

Schedule of Inventories

Inventories are stated at lower of cost (at standard cost which approximates the first-in, first-out method) or market. Inventories consist of the following:


	Nov 30, 2013		May 31, 2013
	(in thousands)
Raw materials	$	24,287	$	18,362
Work in process		11,557		11,006
Finished goods		24,208		25,694

Inventories	$	60,052	$	55,062

Goodwill and Intangible Assets (Tables)

6 Months Ended

Nov. 30, 2013

Goodwill And Intangible Assets Disclosure [Abstract]

Goodwill by Segment

Adjustments to goodwill for the six months ended November 30, 2013 are as follows (in thousands):


Balance, May 31, 2013	$	355,458
Acquisition of Clinical Devices B.V.		4,278

Balance, November 30, 2013	$	359,736

Intangible Assets

The balances of intangible assets are as follows:


	November 30, 2013
	Gross carrying value		Accumulated amortization			Net carrying value		Weighted avg useful life
			(in thousands)					(years)
Product technologies	$	149,111	$	(28,623	)	$	120,488		10.3
Customer relationships		86,640		(34,593	)		52,047		11.9
Trademark-NAMIC		28,600		—			28,600		Indefinite
Licenses		7,540		(4,949	)		2,591		7.5
Trademarks		6,345		(1,476	)		4,869		8.0
In-process R&D acquired		3,600		—			3,600		Indefinite
Distributor relationships		900		(900	)		—		3.0

	$	282,736	$	(70,541	)	$	212,195


	May 31, 2013
	Gross carrying value		Accumulated amortization			Net carrying value		Weighted avg useful life
			(in thousands)					(years)
Product technologies	$	150,181	$	(24,835	)	$	125,346		10.6
Customer relationships		84,479		(30,595	)		53,884		14.8
Trademark-NAMIC		28,600		—			28,600		Indefinite
Licenses		6,302		(4,501	)		1,801		9.0
Trademarks		6,275		(1,058	)		5,217		9.9
Distributor relationships		900		(900	)		—		3.0

	$	276,737	$	(61,889	)	$	214,848

Accrued Liabilities (Tables)

6 Months Ended

Nov. 30, 2013

Payables And Accruals [Abstract]

Accrued Liabilities

Accrued liabilities consist of the following:


	Nov 30, 2013		May 31, 2013
	(in thousands)
Payroll and related expenses	$	6,217	$	6,491
Royalties		2,084		2,034
Income taxes payable		741		—
Deferred revenue		1,616		1,573
Accrued severance		1,200		1,602
Sales and franchise taxes		1,329		1,047
Interest rate swap liability		725		523
Other		3,618		3,156

Total	$	17,530	$	16,426

Earnings Per Common Share (Tables)

6 Months Ended

Nov. 30, 2013

Earnings Per Share [Abstract]

Reconciliation of Weighted-Average Number of Common Shares

The following table sets forth the reconciliation of the weighted-average number of common shares (in thousands):


	Three Months Ended				Six Months Ended
	Nov 30, 2013		Nov 30, 2012		Nov 30, 2013		Nov 30, 2012
Basic		35,132		34,827		35,041		34,765
Effect of dilutive securities		0		484		0		514

Diluted		35,132		35,311		35,041		35,279

Segment and Geographic Information (Tables)

6 Months Ended

Nov. 30, 2013

Segment Reporting [Abstract]

Summary of Net Sales by Product Category

Net sales by product category are summarized below (in thousands):


	Three Months Ended				Six Months Ended
	Nov 30, 2013		Nov 30, 2012		Nov 30, 2013		Nov 30, 2012
Net sales
Peripheral Vascular	$	48,860	$	45,766	$	94,340	$	89,060
Vascular Access		25,571		26,712		50,854		53,342
Oncology/Surgery		12,557		12,006		23,724		23,239
Supply Agreement		1,628		2,523		3,277		4,782

Total	$	88,616	$	87,007	$	172,195	$	170,423

Summary of Net Sales for Geographic Areas

Net sales for geographic areas, based on external customer location, are summarized below (in thousands):


	Three Months Ended				Six Months Ended
	Nov 30, 2013		Nov 30, 2012		Nov 30, 2013		Nov 30, 2012
Net Sales
United States	$	69,530	$	67,129	$	136,632	$	132,898
International		17,458		17,355		32,286		32,743
Supply Agreement		1,628		2,523		3,277		4,782

Total	$	88,616	$	87,007	$	172,195	$	170,423

Fair Value (Tables)

6 Months Ended

Nov. 30, 2013

Fair Value Disclosures [Abstract]

Fair Value of Assets and Liabilities Measured on a Recurring Basis

The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis (in thousands):


	Fair Value Measurements using inputs considered as:						Fair Value at November 30, 2013
	Fair Value Measurements using inputs considered as:
	Level 1		Level 2		Level 3
Financial Assets
Cash equivalents
Money market funds	$	420	$	—	$	—	$	420

Total	$	420	$	—	$	—	$	420

Marketable securities
U.S. government agency obligations	$	—	$	—	$	1,850	$	1,850

Total		—		—		1,850		1,850

Total Financial Assets	$	420	$	—	$	1,850	$	2,270


Financial Liabilities
Interest rate swap agreements	$	—	$	725	$	—	$	725
Contingent liability for acquisition earn out		—		—		72,392		72,392

Total Financial Liabilities	$	—	$	725	$	72,392	$	73,117


	Fair Value Measurements using inputs considered as:						Fair Value at May 31, 2013
	Fair Value Measurements using inputs considered as:
	Level 1		Level 2		Level 3
Financial Assets
Cash equivalents
Money market funds	$	114	$	—	$	—	$	114

Total	$	114	$	—	$	—	$	114

Marketable securities
Corporate bond securities	$	—	$	303	$	—	$	303
U.S. government agency obligations		—		—		1,850		1,850

Total		—		303		1,850		2,153

Total Financial Assets	$	114	$	303	$	1,850	$	2,267


Financial Liabilities
Interest rate swap agreements	$	—	$	522	$	—	$	522
Contingent liability for acquisition earn out						75,049		75,049

Total Financial Liabilities	$	—	$	522	$	75,049	$	75,571

Fair Value Measurements Using Significant Unobservable Inputs

The components of Level 3 fair value instruments as of November 30, 2013 are shown below (in thousands):


	Financial Assets		Financial Liabilities
	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)		Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Balance, May 31, 2013	$	1,850	$	75,049
Total gains or losses (realized/unrealized):		—		—
Included in earnings		—		1,673
Included in other comprehensive income		—		—
Purchases, issuances and settlements		—		(9,300	)
Transfers in and/or (out) of Level 3		—		—
Contingent consideration - Clinical Devices		—		4,970

Balance, November 30, 2013	$	1,850	$	72,392

Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability


	Fair value at Nov 30, 2013		Valuation Technique	Unobservable Input	Range
Revenue based payments	$	68.1	Discounted	Discount rate	4%-10%
			cash flow	Probability of payment	75-100%
				Projected fiscal year of payment	2014-2022

Milestone based payments	$	4.3	Discounted	Discount rate	16%-20%
			cash flow	Probability of payment	75-100%
				Projected fiscal year of payment	2014-2015

Total	$	72.4

Summary Showing Reconciliation of the Contingent Payments


Beginning balance - May 31, 2013	$	75.0
Purchase price contingent consideration		5.0
Contingent payments		(9.3	)
Change in fair value of contingent consideration		1.7

Ending balance - November 30, 2013	$	72.4

Marketable Securities (Tables)

6 Months Ended

Nov. 30, 2013

Investments Debt And Equity Securities [Abstract]

Marketable Securities

Marketable securities as of November 30, 2013 consisted of the following:


	Amortized cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
	(in thousands)
Available-for-sales securities
U.S. government agency obligations	$	1,850	$	—	$	—	$	1,850

	$	1,850	$	—	$	—	$	1,850

Marketable securities as of May 31, 2013 consisted of the following:


	Amortized cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
	(in thousands)
Available-for-sales securities
U.S. government agency obligations	$	1,850	$	—	$	—	$	1,850
Corporate bond securities		303		—		—		303

	$	2,153	$	—	$	—	$	2,153

Consolidated Financial Statements - Additional Information (Detail) $ in Millions		1 Months Ended					3 Months Ended		6 Months Ended
	Dec. 05, 2013 USD ($) Employees	Sep. 19, 2013 USD ($) Agreement	Nov. 28, 2012 Observations	Sep. 24, 2012 Observations	Feb. 13, 2012 Observations	Feb. 10, 2012 Observations	Nov. 30, 2013 USD ($)	Nov. 30, 2012 USD ($)	Nov. 30, 2013 USD ($)	Nov. 30, 2012 USD ($)
Recent Developments [Line Items]
Costs for Quality Call to Action Program									$ 3.2
Number of observations \| Observations			0	5	6	12
Number of business days to provide response to FDA									15 days
Clinical Devices B.V [Member]
Recent Developments [Line Items]
Date of business acquisition									Aug. 15, 2013
Navilyst [Member]
Recent Developments [Line Items]
Transaction and severance costs related to acquisition							$ 1.6	$ 1.7	$ 2.8	$ 3.9
Subsequent Event [Member]
Recent Developments [Line Items]
Operational excellence program period	3 years
Subsequent Event [Member] \| Minimum [Member]
Recent Developments [Line Items]
Expected savings due to operational excellence program over three years	$ 15.0
Number of employees to be reduced \| Employees	80
Subsequent Event [Member] \| Maximum [Member]
Recent Developments [Line Items]
Expected savings due to operational excellence program over three years	$ 18.0
Number of employees to be reduced \| Employees	100
New Credit Agreement [Member]
Recent Developments [Line Items]
Percentage of increase in interest		2.00%
Number of financial covenants \| Agreement		2
New Credit Agreement [Member] \| Minimum [Member]
Recent Developments [Line Items]
Covenant ratio range		Not less than 1.35 to 1.00
New Credit Agreement [Member] \| Maximum [Member]
Recent Developments [Line Items]
Covenant ratio range		Not greater than 3.75 to 1.00
New Credit Agreement [Member] \| Term Loan Facility [Member]
Recent Developments [Line Items]
Senior secured term loan facility		$ 100.0
Percentage of quarterly repayment of term facility year one		5.00%
Percentage of quarterly repayment of term facility year two		5.00%
Percentage of quarterly repayment of term facility year three		10.00%
Percentage of quarterly repayment of term facility year four		15.00%
Percentage of quarterly repayment of term facility year five		65.00%
Bank credit agreement maturity period		In years one through five
Credit facility, amount outstanding							98.8		98.8
New Credit Agreement [Member] \| Senior Secured Revolving Credit Facility [Member]
Recent Developments [Line Items]
Senior secured term loan facility		$ 100.0
New Credit Agreement [Member] \| Senior Secured Revolving Credit Facility [Member] \| Minimum [Member]
Recent Developments [Line Items]
Commitment fee percentage		0.20%
New Credit Agreement [Member] \| Senior Secured Revolving Credit Facility [Member] \| Maximum [Member]
Recent Developments [Line Items]
Commitment fee percentage		0.35%
New Credit Agreement [Member] \| Letters of Credit [Member]
Recent Developments [Line Items]
Senior secured term loan facility		$ 20.0
New Credit Agreement [Member] \| Swingline Loans [Member]
Recent Developments [Line Items]
Senior secured term loan facility		5.0
New Credit Agreement [Member] \| Revolving Credit Facility [Member]
Recent Developments [Line Items]
Initial amount borrowed under revolving facility		$ 41.4
Credit facility, amount outstanding							$ 41.4		$ 41.4
New Credit Agreement [Member] \| Base Rate [Member] \| JP Morgan Chase [Member]
Recent Developments [Line Items]
Percentage of increases leverage ratio base rate, minimum		0.50%
Percentage of increases leverage ratio base rate, maximum		1.25%
New Credit Agreement [Member] \| Eurodollar [Member] \| JP Morgan Chase [Member]
Recent Developments [Line Items]
Percentage of increases leverage ratio base rate, minimum		1.50%
Percentage of increases leverage ratio base rate, maximum		2.25%

Acquisitions - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended	6 Months Ended	12 Months Ended
	Aug. 15, 2013	Nov. 30, 2013	Nov. 30, 2013	May 31, 2013	Dec. 31, 2013	Feb. 01, 2013
Business Acquisition [Line Items]
Goodwill acquired		$ 359,736,000	$ 359,736,000	$ 355,458,000
Minimum [Member]
Business Acquisition [Line Items]
Weighted average useful life			3 years
Maximum [Member]
Business Acquisition [Line Items]
Weighted average useful life			15 years
Clinical Devices B.V [Member]
Business Acquisition [Line Items]
Cash payments at closing total	$ 3,700,000
Business acquisition purchase price holdback amount	400,000
Total purchase	8,700,000
Present value of contingent consideration liability	5,000,000
Goodwill acquired	4,300,000
Intangible assets other than goodwill	5,100,000
Deferred tax liabilities	1,200,000
Microsulis Medical Ltd. [Member]
Business Acquisition [Line Items]
Cash payments at closing total		10,500,000	$ 10,500,000			$ 10,000,000
Total purchase		33,600,000	33,600,000
Present value of contingent consideration liability		13,200,000	13,200,000
Goodwill acquired		19,300,000	19,300,000
Business acquisition cost of acquired entity purchase price payable		5,000,000	$ 5,000,000			5,000,000
Liabilities assumed						$ 1,600,000
Additional cash consideration payable period			9 years
Investment in company		5,000,000	$ 5,000,000
Acquisition related costs		0	$ 60,000
Microsulis Medical Ltd. [Member] \| Minimum [Member]
Business Acquisition [Line Items]
Weighted average useful life			10 years
Microsulis Medical Ltd. [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Weighted average useful life			15 years
Microsulis Medical Ltd. [Member] \| Subsequent Event [Member]
Business Acquisition [Line Items]
Total purchase					$ 5,000,000
Vortex Medical, Inc. [Member]
Business Acquisition [Line Items]
Cash payments at closing total		15,100,000	$ 15,100,000
Total purchase		75,300,000	75,300,000
Present value of contingent consideration liability		60,300,000	60,300,000
Goodwill acquired		29,500,000	29,500,000
Fair value of guaranteed contingent consideration		$ 40,000,000	$ 40,000,000
Weighted average useful life			15 years
In-Process Research and Development [Member] \| Clinical Devices B.V [Member]
Business Acquisition [Line Items]
Acquired finite lived intangible assets	$ 3,600,000
Weighted average useful life	10 years
Customer Relationships [Member]
Business Acquisition [Line Items]
Weighted average useful life			11 years 10 months 24 days	14 years 9 months 18 days
Customer Relationships [Member] \| Clinical Devices B.V [Member]
Business Acquisition [Line Items]
Acquired finite lived intangible assets	$ 1,400,000
Weighted average useful life	15 years
Trademarks [Member]
Business Acquisition [Line Items]
Weighted average useful life			8 years	9 years 10 months 24 days
Trademarks [Member] \| Clinical Devices B.V [Member]
Business Acquisition [Line Items]
Acquired finite lived intangible assets	$ 100,000
Weighted average useful life	5 years

Inventories - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Nov. 30, 2013	May 31, 2013
Inventory Disclosure [Abstract]
Raw materials	$ 24,287	$ 18,362
Work in process	11,557	11,006
Finished goods	24,208	25,694
Inventories	$ 60,052	$ 55,062

Goodwill and Intangible Assets - Additional Information (Detail) $ in Millions	1 Months Ended	6 Months Ended
	Dec. 31, 2012 USD ($)	Nov. 30, 2013 Segment Reporting_Unit
Finite-Lived Intangible Assets [Line Items]
Number of reportable unit \| Reporting_Unit		1
Number of operating segment \| Segment		1
Terminal value of the reporting unit		6.0
Discount rate used in fair value calculation		13.50%
Percentage of fair value, carrying value	5.00%
Estimated control premium used in fair value calculation	60.00%
Goodwill impairment \| $	$ 0
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of intangible assets other than goodwill		15 years
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of intangible assets other than goodwill		3 years

Goodwill and Intangible Assets - Goodwill by Segment (Detail) $ in Thousands	6 Months Ended
	Nov. 30, 2013 USD ($)
Goodwill [Line Items]
Goodwill, Beginning Balance	$ 355,458
Goodwill, Ending Balance	359,736
Clinical Devices B.V [Member]
Goodwill [Line Items]
Acquisition	$ 4,278

Goodwill and Intangible Assets - Intangible Assets (Detail) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Nov. 30, 2013	May 31, 2013
Schedule Of Intangible Assets [Line Items]
Gross carrying value	$ 282,736	$ 276,737
Accumulated amortization	(70,541)	(61,889)
Net carrying value	212,195	214,848
Product Technologies [Member]
Schedule Of Intangible Assets [Line Items]
Gross carrying value	149,111	150,181
Accumulated amortization	(28,623)	(24,835)
Net carrying value	$ 120,488	$ 125,346
Weighted avg useful life	10 years 3 months 18 days	10 years 7 months 6 days
Customer Relationships [Member]
Schedule Of Intangible Assets [Line Items]
Gross carrying value	$ 86,640	$ 84,479
Accumulated amortization	(34,593)	(30,595)
Net carrying value	$ 52,047	$ 53,884
Weighted avg useful life	11 years 10 months 24 days	14 years 9 months 18 days
Licenses [Member]
Schedule Of Intangible Assets [Line Items]
Gross carrying value	$ 7,540	$ 6,302
Accumulated amortization	(4,949)	(4,501)
Net carrying value	$ 2,591	$ 1,801
Weighted avg useful life	7 years 6 months	9 years
Trademarks [Member]
Schedule Of Intangible Assets [Line Items]
Gross carrying value	$ 6,345	$ 6,275
Accumulated amortization	(1,476)	(1,058)
Net carrying value	$ 4,869	$ 5,217
Weighted avg useful life	8 years	9 years 10 months 24 days
Distributor Relationships [Member]
Schedule Of Intangible Assets [Line Items]
Gross carrying value	$ 900	$ 900
Accumulated amortization	(900)	(900)
Net carrying value
Weighted avg useful life	3 years	3 years
Trademark-NAMIC [Member]
Schedule Of Intangible Assets [Line Items]
Gross carrying value	$ 28,600	$ 28,600
Accumulated amortization
Net carrying value	28,600	$ 28,600
In-Process Research and Development [Member]
Schedule Of Intangible Assets [Line Items]
Gross carrying value	3,600
Accumulated amortization
Net carrying value	$ 3,600

Accrued Liabilities - Summary of Accrued Liabilities (Detail) - USD ($) $ in Thousands	Nov. 30, 2013	May 31, 2013
Other Liabilities Disclosure [Abstract]
Payroll and related expenses	$ 6,217	$ 6,491
Royalties	2,084	2,034
Income taxes payable	741
Deferred revenue	1,616	1,573
Accrued severance	1,200	1,602
Sales and franchise taxes	1,329	1,047
Interest rate swap liability	725	523
Other	3,618	3,156
Total	$ 17,530	$ 16,426

Long Term Debt - Additional Information (Detail) $ in Millions	1 Months Ended
	Sep. 19, 2013 USD ($) Agreement	Nov. 30, 2013 USD ($)
Debt Instrument [Line Items]
Notional amount of interest rate swap agreement		$ 100.0
Fixed interest rate payments		0.74%
New Credit Agreement [Member]
Debt Instrument [Line Items]
Percentage of increase in interest	2.00%
Number of financial covenants \| Agreement	2
New Credit Agreement [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Covenant ratio range	Not less than 1.35 to 1.00
New Credit Agreement [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Covenant ratio range	Not greater than 3.75 to 1.00
New Credit Agreement [Member] \| Base Rate [Member] \| JP Morgan Chase [Member]
Debt Instrument [Line Items]
Percentage of increases leverage ratio base rate, minimum	0.50%
Percentage of increases leverage ratio base rate, maximum	1.25%
New Credit Agreement [Member] \| Eurodollar [Member] \| JP Morgan Chase [Member]
Debt Instrument [Line Items]
Percentage of increases leverage ratio base rate, minimum	1.50%
Percentage of increases leverage ratio base rate, maximum	2.25%
New Credit Agreement [Member] \| Term Loan Facility [Member]
Debt Instrument [Line Items]
Senior secured term loan facility	$ 100.0
Percentage of quarterly repayment of term facility year one	5.00%
Percentage of quarterly repayment of term facility year two	5.00%
Percentage of quarterly repayment of term facility year three	10.00%
Percentage of quarterly repayment of term facility year four	15.00%
Percentage of quarterly repayment of term facility year five	65.00%
Bank credit agreement maturity period	In years one through five
Credit facility, amount outstanding		$ 98.8
New Credit Agreement [Member] \| Senior Secured Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Senior secured term loan facility	$ 100.0
New Credit Agreement [Member] \| Senior Secured Revolving Credit Facility [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Commitment fee percentage	0.20%
New Credit Agreement [Member] \| Senior Secured Revolving Credit Facility [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Commitment fee percentage	0.35%
New Credit Agreement [Member] \| Letters of Credit [Member]
Debt Instrument [Line Items]
Senior secured term loan facility	$ 20.0
New Credit Agreement [Member] \| Swingline Loans [Member]
Debt Instrument [Line Items]
Senior secured term loan facility	5.0
New Credit Agreement [Member] \| Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Initial amount borrowed under revolving facility	$ 41.4
Credit facility, amount outstanding		$ 41.4

Income Taxes - Additional Information (Detail)	3 Months Ended		6 Months Ended
Income Taxes - Additional Information (Detail)	Nov. 30, 2013	Nov. 30, 2012	Nov. 30, 2013	Nov. 30, 2012
Income Tax Disclosure [Abstract]
Effective income tax rate	15.00%	37.00%	(28.00%)	37.00%
R&D tax credit expired date			Dec. 31, 2013

Earnings Per Common Share - Reconciliation of Weighted-Average Number of Common Shares (Detail) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2013	Nov. 30, 2012	Nov. 30, 2013	Nov. 30, 2012
Earnings Per Share [Abstract]
Basic	35,132	34,827	35,041	34,765
Effect of dilutive securities	0	484	0	514
Diluted	35,132	35,311	35,041	35,279

Earnings Per Common Share - Additional Information (Detail) - shares shares in Millions	3 Months Ended		6 Months Ended
	Nov. 30, 2013	Nov. 30, 2012	Nov. 30, 2013	Nov. 30, 2012
Earnings Per Share [Abstract]
Antidilutive securities excluded from computation of diluted earnings per share	2.3	3.2	2.7	3.0

Segment and Geographic Information - Additional Information (Detail)	6 Months Ended
	Nov. 30, 2013 Segment
Segment Reporting [Abstract]
Number of segment	1

Segment and Geographic Information - Summary of Net Sales by Product Category (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2013	Nov. 30, 2012	Nov. 30, 2013	Nov. 30, 2012
Segment Reporting Information [Line Items]
Net sales	$ 88,616	$ 87,007	$ 172,195	$ 170,423
Operating Segments [Member] \| Peripheral Vascular [Member]
Segment Reporting Information [Line Items]
Net sales	48,860	45,766	94,340	89,060
Operating Segments [Member] \| Vascular Access [Member]
Segment Reporting Information [Line Items]
Net sales	25,571	26,712	50,854	53,342
Operating Segments [Member] \| Oncology/Surgery [Member]
Segment Reporting Information [Line Items]
Net sales	12,557	12,006	23,724	23,239
Operating Segments [Member] \| Supply Agreement [Member]
Segment Reporting Information [Line Items]
Net sales	$ 1,628	$ 2,523	$ 3,277	$ 4,782

Segment and Geographic Information - Summary of Net Sales for Geographic Areas (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2013	Nov. 30, 2012	Nov. 30, 2013	Nov. 30, 2012
Net Sales
Net sales	$ 88,616	$ 87,007	$ 172,195	$ 170,423
Reportable Geographical Components [Member] \| United States [Member]
Net Sales
Net sales	69,530	67,129	136,632	132,898
Reportable Geographical Components [Member] \| International [Member]
Net Sales
Net sales	17,458	17,355	32,286	32,743
Reportable Geographical Components [Member] \| Supply Agreement [Member]
Net Sales
Net sales	$ 1,628	$ 2,523	$ 3,277	$ 4,782

Fair Value - Fair Value of Assets and Liabilities Measured on a Recurring Basis (Detail) - Recurring [Member] - USD ($) $ in Thousands	Nov. 30, 2013	May 31, 2013
Financial Assets
Cash equivalents	$ 420	$ 114
Marketable securities	1,850	2,153
Total Financial Assets	2,270	2,267
Financial Liabilities
Total Financial Liabilities	73,117	75,571
Money Market Funds [Member]
Financial Assets
Cash equivalents	420	114
Corporate Bond Securities [Member]
Financial Assets
Marketable securities		303
U.S. Government Agency Obligations [Member]
Financial Assets
Marketable securities	1,850	1,850
Interest Rate Swap Agreements [Member]
Financial Liabilities
Total Financial Liabilities	725	522
Contingent Consideration Earn Out Liability [Member]
Financial Liabilities
Total Financial Liabilities	72,392	75,049
Level 1 [Member]
Financial Assets
Cash equivalents	420	114
Marketable securities
Total Financial Assets	420	114
Financial Liabilities
Total Financial Liabilities
Level 1 [Member] \| Money Market Funds [Member]
Financial Assets
Cash equivalents	420	114
Level 1 [Member] \| Corporate Bond Securities [Member]
Financial Assets
Marketable securities
Level 1 [Member] \| U.S. Government Agency Obligations [Member]
Financial Assets
Marketable securities
Level 1 [Member] \| Interest Rate Swap Agreements [Member]
Financial Liabilities
Total Financial Liabilities
Level 1 [Member] \| Contingent Consideration Earn Out Liability [Member]
Financial Liabilities
Total Financial Liabilities
Level 2 [Member]
Financial Assets
Cash equivalents
Marketable securities		303
Total Financial Assets		303
Financial Liabilities
Total Financial Liabilities	725	522
Level 2 [Member] \| Money Market Funds [Member]
Financial Assets
Cash equivalents
Level 2 [Member] \| Corporate Bond Securities [Member]
Financial Assets
Marketable securities		303
Level 2 [Member] \| U.S. Government Agency Obligations [Member]
Financial Assets
Marketable securities
Level 2 [Member] \| Interest Rate Swap Agreements [Member]
Financial Liabilities
Total Financial Liabilities	725	522
Level 2 [Member] \| Contingent Consideration Earn Out Liability [Member]
Financial Liabilities
Total Financial Liabilities
Level 3 [Member]
Financial Assets
Cash equivalents
Marketable securities	1,850	1,850
Total Financial Assets	1,850	1,850
Financial Liabilities
Total Financial Liabilities	72,392	75,049
Level 3 [Member] \| Money Market Funds [Member]
Financial Assets
Cash equivalents
Level 3 [Member] \| Corporate Bond Securities [Member]
Financial Assets
Marketable securities
Level 3 [Member] \| U.S. Government Agency Obligations [Member]
Financial Assets
Marketable securities	1,850	1,850
Level 3 [Member] \| Interest Rate Swap Agreements [Member]
Financial Liabilities
Total Financial Liabilities
Level 3 [Member] \| Contingent Consideration Earn Out Liability [Member]
Financial Liabilities
Total Financial Liabilities	$ 72,392	$ 75,049

Fair Value - Fair Value Measurements Using Significant Unobservable Inputs (Detail) $ in Thousands	6 Months Ended
	Nov. 30, 2013 USD ($)
Fair Value Liabilities Measured On Recurring and Nonrecurring Basis [Line Items]
Balance, May 31, 2013, Financial Assets	$ 1,850
Total gains or losses (realized/unrealized):
Included in earnings, Financial Assets
Included in other comprehensive income, Financial Assets
Purchases, issuances and settlements, Financial Assets
Transfers in and/or (out) of Level 3, Financial Assets
Balance, November 30, 2013, Financial Assets	1,850
Balance, May 31, 2013, Financial Liabilities	75,049
Included in earnings, Financial Liabilities	1,673
Included in other comprehensive income, Financial Liabilities
Purchases, issuances and settlements, Financial Liabilities	(9,300)
Transfers in and/or (out) of Level 3, Financial Liabilities
Balance, November 30, 2013, Financial Liabilities	72,392
Clinical Devices B.V [Member]
Total gains or losses (realized/unrealized):
Contingent consideration - Clinical Devices, Financial Assets
Contingent consideration - Clinical Devices, Financial Liabilities	$ 4,970

Fair Value - Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability (Detail) - USD ($) $ in Thousands	6 Months Ended
	Nov. 30, 2013	May 31, 2013
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]
Revenue based payments	$ 72,392	$ 75,049
Level 3 [Member] \| Contingent Consideration Earn Out Liability [Member]
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]
Revenue based payments	72,400
Level 3 [Member] \| Revenue Based Payments [Member] \| Recurring [Member] \| Contingent Consideration Earn Out Liability [Member]
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]
Revenue based payments	$ 68,100
Level 3 [Member] \| Revenue Based Payments [Member] \| Minimum [Member] \| Recurring [Member] \| Contingent Consideration Earn Out Liability [Member]
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]
Discount rate	4.00%
Probability of payment	75.00%
Projected fiscal year of payment	2014
Level 3 [Member] \| Revenue Based Payments [Member] \| Maximum [Member] \| Recurring [Member] \| Contingent Consideration Earn Out Liability [Member]
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]
Discount rate	10.00%
Probability of payment	100.00%
Projected fiscal year of payment	2022
Level 3 [Member] \| Milestone Based Payments [Member] \| Recurring [Member] \| Contingent Consideration Earn Out Liability [Member]
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]
Revenue based payments	$ 4,300
Level 3 [Member] \| Milestone Based Payments [Member] \| Minimum [Member] \| Recurring [Member] \| Contingent Consideration Earn Out Liability [Member]
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]
Discount rate	16.00%
Probability of payment	75.00%
Projected fiscal year of payment	2014
Level 3 [Member] \| Milestone Based Payments [Member] \| Maximum [Member] \| Recurring [Member] \| Contingent Consideration Earn Out Liability [Member]
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]
Discount rate	20.00%
Probability of payment	100.00%
Projected fiscal year of payment	2015

Fair Value - Additional Information (Detail) $ in Millions	Nov. 30, 2013 USD ($)
Fair Value Disclosures [Abstract]
Potential amount of undiscounted future contingent consideration	$ 91.7
Fair value of contingent milestone payments, long term portion	60.2
Fair value of contingent milestone payments, current portion	$ 12.2

Fair Value - Summary Showing Reconciliation of the Contingent Payments (Detail) - Contingent Consideration Earn Out Liability [Member] - Vortex, Microsulis and Clinical Devices [Member]	6 Months Ended
	Nov. 30, 2013 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance - May 31, 2013	$ 75,000
Purchase price contingent consideration	5,000
Contingent payments	(9,300)
Change in fair value of contingent consideration	1,700
Ending balance - November 30, 2013	$ 72,400

Marketable Securities - Additional Information (Detail) $ in Thousands	Nov. 30, 2013 USD ($) Investment	May 31, 2013 USD ($) Investment
Amortized Cost And Fair Value Debt Securities [Abstract]
Investments in auction rate securities that failed auctions \| $	$ 1,850	$ 1,850
Number of investments \| Investment	2	2

Marketable Securities - Marketable Securities (Detail) - USD ($) $ in Thousands	Nov. 30, 2013	May 31, 2013
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	$ 1,850	$ 2,153
Gross Unrealized Gains
Gross Unrealized Losses
Fair Value	1,850	2,153
U.S. Government Agency Obligations [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	1,850	1,850
Gross Unrealized Gains
Gross Unrealized Losses
Fair Value	$ 1,850	1,850
Corporate Bond Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized cost		303
Gross Unrealized Gains
Gross Unrealized Losses
Fair Value		$ 303

Litigation - Additional Information (Detail) $ in Millions	1 Months Ended	6 Months Ended
Litigation - Additional Information (Detail) $ in Millions	Nov. 08, 2012 USD ($)	Nov. 30, 2013 Lawsuits Petition
Biolitec [Member]
Loss Contingencies [Line Items]
Number of lawsuits against biolitec previously settled for which seeking defense and indemnification \| Lawsuits		2
Partial judgment granted \| $	$ 23.2
C.R. Bard, Inc. [Member]
Loss Contingencies [Line Items]
Number of petitions filed for reexamination of patents \| Petition		3
Number of patent claims rejected		40 of 41 patent

Recently Issued Accounting Pronouncements - Additional Information (Detail)	6 Months Ended
	Nov. 30, 2013
Accounting Policies [Abstract]
Indefinite-lived intangible asset impairment threshold	More than 50%

Subsequent Events - Additional Information (Detail) - Subsequent Event [Member] $ in Millions	Dec. 05, 2013 USD ($) Employees
Subsequent Event [Line Items]
Operational excellence program period	3 years
Minimum [Member]
Subsequent Event [Line Items]
Expected savings due to operational excellence program over three years \| $	$ 15
Number of employees to be reduced \| Employees	80
Maximum [Member]
Subsequent Event [Line Items]
Expected savings due to operational excellence program over three years \| $	$ 18
Number of employees to be reduced \| Employees	100